On Jan. 5, 2023, Novavax announced that Spain�s Public Health Commission, Italy�s Ministry of Health, and France�s Haute Autorit� de Sant� released updated recommendations expanding use of Nuvaxovid�(NVX-CoV2373) in their respective countries.

Novavax� COVID-19 vaccine is authorized for use as an adult booster in more than 35 countries, and a number of other countries have policy recommendations allowing use of the vaccine as a booster dose. The vaccine is also authorized for use in adolescents aged 12 through 17 in more than 30 markets around the world, including the�U.S., member states in the�European Union, and the�United Kingdom.